Navigation Links
Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
Date:11/22/2009

A protein known to stimulate blood vessel growth has now been found to be responsible for the cell overgrowth in the development of polyps that characterize one of the most severe forms of sinusitis, a study by Johns Hopkins researchers suggests. The finding gives scientists a new target for developing novel therapies to treat this form of the disease, which typically resists all current treatments.

Chronic sinusitis, a constant irritation and swelling of the nasal passages, is a common condition thought to affect about one out of every six people. This problem has several forms with a range of severities. One of the most severe forms produces polyps, overgrowths of unhealthy sinus tissue that can block the nose and sinus passages and make breathing through the nose difficult or impossible. This often results in pain, swelling, and an increase in infections. Though researchers aren't sure how many people have this subtype, it's estimated to affect between 15 and 30 percent of sinusitis patients.

"This type of sinusitis isn't subtleyou can spot the patients with polyps from across the room. They're breathing through their mouths, they talk with nasal voices, they're constantly sniffling, and their faces are swollen," says Jean Kim, M.D., Ph.D., assistant professor in the Departments of Otolaryngology and Allergy and Clinical Immunology at the Johns Hopkins University School of Medicine, and a researcher at the Johns Hopkins Allergy and Asthma Center at the Johns Hopkins Bayview Medical Center.

Kim explains that surgery to remove the polyps is one of the most common treatments for this disease. However, nasal and sinus polyps in these patients almost always regrow. "Once the patient has entered the cycle of growing polyps, it's very hard to get out," she says. Another common treatment is oral steroids, but these drugs are fraught with many harmful side effects and also only temporarily treat the disease.

She and her Johns Hopkins colleagues have long studied sinusitis, often growing sinus cells isolated from patients in petri dishes. After noticing that cells from patients with polyps typically multiplied faster than cells from normal patients, the researchers speculated that cells from polyp patients might be producing extra amounts of some type of growth factor, a protein that encourages cell growth.

To identify which growth factor might be to blame, the researchers had sinusitis patients with and without polyps rinse their sinus passages with a wash solution, then tested the runoff for the presence of various growth factors. They found that solution from patients with polyps contained high amounts of a substance called vascular endothelial growth factor, or VEGF, a protein important for normal blood vessel growth that also seems to play a key role in a variety of diseases, including cancer. The more VEGF they found in a cell culture, the faster those cells grew.

To further examine whether this protein is present not only in the sinus passages but also in the sinus tissue, Kim and her colleagues used a stain that highlights VEGF on sinus tissue removed from polyp-producing patients and those with other types of sinusitis. The stained tissue from polyp patients "lit up very dramatically, like a city skyline," Kim says, while the tissue from other patients showed little to no staining.

Though these results confirmed that the sinuses of patients with polyps were overproducing VEGF, the researchers still weren't sure that VEGF was instigating cell overgrowth seen in polyps. Looking for a cause-and-effect relationship, Kim and her team treated cells isolated from sinusitis patients with agents that inhibit VEGF production and action. The cells from polyp-producing patients slowed their growth rate to match that of normal patients.

"It's a strong indicator that VEGF is indeed responsible for the over-exuberant cell growth that contributes to polyp development," Kim says.

Her findings, published in the Dec. 1 American Journal of Respiratory and Critical Care Medicine, suggest that doctors may eventually treat sinusitis in patients with polyps using therapies that reduce VEGF in sinus tissues. "In the future, we might have a nasal spray with an anti-VEGF agent in it," she proposes.

The results also suggest a new way of predicting which patients will go on to develop polyps. They might also simplify tracking the progression of the disease, a process which now relies on repeated CT-scans, which expose patients to radiation. Since many patients with polyps already use sinus washes to ease their symptoms, doctors may be able to use any VEGF present in the runoff from these washes as a marker for the disease and its severity.


'/>"/>

Contact: Christen Brownlee
cbrownlee@jhmi.edu
410-955-7832
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. SC Johnson Makes Commitment to Clinton Global Initiative
2. CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine
3. EF Johnson Technologies, Inc. Announces Third Quarter Financial Reporting Date
4. Robert Wood Johnson Foundation, The Pew Charitable Trusts Launch National Initiative to Advance Policies That Promote Health
5. Johnson Matthey Expands San Diego Facility
6. Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Medical Devices & Diagnostics Business
7. Johns Hopkins epigenetic center receives $16.8 million NIH grant
8. SC Johnson a Best Company for Working Moms
9. SC Johnson Joins Conservation Internationals Team Earth, a Worldwide Sustainability Movement, As One of the Founding Members
10. EF Johnson Technologies, Inc. Receives Notice Regarding Minimum Bid Price Rule
11. Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimers Immunotherapy Program and Equity Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds ... the launch of a new DRTV campaign with Belly Bands. , Having a dog ... from sprays to puppy pads and find nothing works, get Belly Bands, the ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 ... ... today announced the availability of the company's lighter, sleeker next generation LYNX VR ... assembly plant. , Improvements in design and manufacturing not only reduce the ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... ... 05, 2016 , ... After years as an active staff surgeon and having ... surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery at ... term as chief and began a second three-year term in January of 2016. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to ... may be safer than regular municipal or well water. The recent experience with lead ... Kleyne, could go a long way toward increasing public acceptance of recycled waste water ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
Breaking Medicine Technology: